Free Trial

MeiraGTx (MGTX) Stock Price, News & Analysis

+0.09 (+2.09%)
(As of 03:39 PM ET)
Today's Range
50-Day Range
52-Week Range
161,364 shs
Average Volume
156,816 shs
Market Capitalization
$282.96 million
P/E Ratio
Dividend Yield
Price Target

MeiraGTx MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
490.9% Upside
$26.00 Price Target
Short Interest
1.91% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.52) to $0.87 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

246th out of 897 stocks

Biological Products, Except Diagnostic Industry

32nd out of 150 stocks

MGTX stock logo

About MeiraGTx Stock (NASDAQ:MGTX)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

MGTX Stock Price History

MGTX Stock News Headlines

Catalyst Could Trigger 10,000% Crypto Gains
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
MeiraGTx (MGTX) Earnings Dates & Reports
Catalyst Could Trigger 10,000% Crypto Gains
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
MGTX Apr 2024 12.500 call
Recap: MeiraGTx Hldgs Q4 Earnings
Meira Retreats on Financial Figures
MGTX Mar 2024 12.500 call
MeiraGTx Holdings PLC MGTX
See More Headlines
Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$14.02 million
Book Value
$2.17 per share


Free Float
Market Cap
$282.96 million
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Alexandria Forbes Ph.D. (Age 59)
    CEO, President & Director
    Comp: $2.89M
  • Mr. Richard Brian Giroux B.A. (Age 51)
    COO & CFO
    Comp: $2.14M
  • Dr. Stuart Naylor Ph.D. (Age 61)
    Chief Development Officer
    Comp: $1.06M
  • Mr. Robert J. Wollin J.D. (Age 48)
    General Counsel & Secretary
  • Dr. Michel Michaelides M.D.
    Head of Clinical Ophthalmology
  • Ms. Christine Elise Sheehy (Age 56)
    Senior Vice President of Global Integration
  • Mr. Tim Randall
    Senior Vice President of Risk & Internal Controls
  • Dr. Alastair Leighton Ph.D.
    Senior Vice President of Manufacturing & Supply Chain
  • Dr. Robert K. Zeldin M.D. (Age 61)
    Chief Medical Officer
    Comp: $1.1M

MGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MeiraGTx stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MGTX shares.
View MGTX analyst ratings
or view top-rated stocks.

What is MeiraGTx's stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for MeiraGTx's stock. Their MGTX share price targets range from $11.00 to $41.00. On average, they expect the company's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 490.9% from the stock's current price.
View analysts price targets for MGTX
or view top-rated stocks among Wall Street analysts.

How have MGTX shares performed in 2024?

MeiraGTx's stock was trading at $7.02 at the start of the year. Since then, MGTX stock has decreased by 37.3% and is now trading at $4.40.
View the best growth stocks for 2024 here

When is MeiraGTx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our MGTX earnings forecast

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) released its earnings results on Thursday, May, 9th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.45. The business earned $0.70 million during the quarter, compared to the consensus estimate of $16.38 million. MeiraGTx had a negative net margin of 651.19% and a negative trailing twelve-month return on equity of 122.82%.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

When did MeiraGTx IPO?

MeiraGTx (MGTX) raised $75 million in an initial public offering on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.50%), Russell Investments Group Ltd. (0.25%), Privium Fund Management B.V. (0.19%), Los Angeles Capital Management LLC (0.18%), CreativeOne Wealth LLC (0.11%) and Tocqueville Asset Management L.P. (0.06%). Insiders that own company stock include Alexandria Forbes, Perceptive Advisors Llc, Richard Giroux, Robert J Wollin, Robert K Zeldin and Stuart Naylor.
View institutional ownership trends

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGTX) was last updated on 6/21/2024 by Staff

From Our Partners